StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.98MP/E –Yield –

Lyell Immunopharma operating margin

Operating margin is operating income as a percentage of revenue.

Lyell Immunopharma's operating margin for the twelve months ending Jun 30, 2026 was -949981.5%. For fiscal 2025 it was -748344.4%, against -588123.0% the year before. The highest annual figure on record is -220.9% in fiscal 2022.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-748344.4%−160221.5
FY2024Dec 31, 2024-588123.0%−398116.8
FY2023Dec 31, 2023-190006.2%−189785.3
FY2022Dec 31, 2022-220.9%+1795.8
FY2021Dec 31, 2021-2016.7%+715.9
FY2020Dec 31, 2020-2732.6%+12806.1
FY2019Dec 31, 2019-15538.7%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1183425.0%−594175.0
Q1 FY2026Mar 31, 2026-2213050.0%−1393521.4
Q4 FY2025Dec 31, 2025-2127400.0%−298790.9
Q3 FY2025Sep 30, 2025-248353.3%−99809.2
Q2 FY2025Jun 30, 2025-589250.0%−192880.8
Q1 FY2025Mar 31, 2025-819528.6%+1032971.4
Q4 FY2024Dec 31, 2024-1828609.1%−1370855.2
Q3 FY2024Sep 30, 2024-148544.1%+87611.9
Q2 FY2024Jun 30, 2024-396369.2%−152276.6
Q1 FY2024Mar 31, 2024-1852500.0%−1756260.0
Q4 FY2023Dec 31, 2023-457753.8%−457723.3
Q3 FY2023Sep 30, 2023-236156.0%+1978410.7
Q2 FY2023Jun 30, 2023-244092.6%−243988.3
Q1 FY2023Mar 31, 2023-96240.0%−83839.3
Q4 FY2022Dec 31, 2022-30.6%+1654.0
Q3 FY2022Sep 30, 2022-2214566.7%−2212782.2
Q2 FY2022Jun 30, 2022-104.3%+2281.9
Q1 FY2022Mar 31, 2022-12400.7%−10136.1
Q4 FY2021Dec 31, 2021-1684.5%+25.0
Q3 FY2021Sep 30, 2021-1784.4%+1658.8
Q2 FY2021Jun 30, 2021-2386.1%+903.4
Q1 FY2021Mar 31, 2021-2264.6%–
Q4 FY2020Dec 31, 2020-1709.5%–
Q3 FY2020Sep 30, 2020-3443.3%–
Q2 FY2020Jun 30, 2020-3289.5%–

More Lyell Immunopharma figures

See a number that looks wrong?